Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

What information is available about switching between Trulicity® (dulaglutide) and other GLP-1 receptor agonists?

Eli Lilly and Company has not sponsored any studies on the effects of switching between dulaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1 RAs).


Indication according to the label

Dulaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for once weekly dosing as an adjunct to diet and exercise for the treatment of adults with insufficiently controlled Type 2 Diabetes mellitus.1

What should I consider when switching?

Physicians should follow their clinical judgment, taking into account the patient’s glycemic response and needs, when deciding how to transition from one GLP-1 RA to another one.2 

When transitioning a patient from one GLP-1 RA to another, the prescribing information of the applicable GLP-1 RAs and pharmacokinetic/pharmacodynamic profiles should be considered including

  • dosing and administration
  • safety profile
  • onset of action
  • duration of action
  • half-life
  • time to steady state, and 
  • missed dose information.2

Please find the mentioned pharmacokinetic properties for dulaglutide in Pharmacokinetic properties of dulaglutide . 

Pharmacokinetic properties of dulaglutide 1,2

Onset of action

Improvement in glycemic control starts after the first administration

Duration of action

Improvement in glycemic control is sustained throughout the once-weekly dosing interval


Approximately 5 days

Time to steady state

Steady state concentrations are achieved within 2 to 4 weeks.

Missing dosing information

Once steady state is achieved, missing 2 or more consecutive doses may result in subtherapeutic dulaglutide concentrations.


1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 24 January 2022

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request